Share on StockTwits

Integra LifeSciences Holdings Corp. (NASDAQ:IART)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Oppenheimer in a research note issued to investors on Wednesday. They currently have a $57.00 price target on the stock, up from their previous price target of $55.00. Oppenheimer’s price target would suggest a potential upside of 17.28% from the company’s current price.

In other Integra LifeSciences Holdings Corp. news, Director Stuart Essig unloaded 50,800 shares of Integra LifeSciences Holdings Corp. stock in a transaction that occurred on Wednesday, July 30th. The stock was sold at an average price of $47.76, for a total value of $2,426,208.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Shares of Integra LifeSciences Holdings Corp. (NASDAQ:IART) traded down 2.82% on Wednesday, hitting $48.60. The stock had a trading volume of 315,622 shares. Integra LifeSciences Holdings Corp. has a 52 week low of $37.39 and a 52 week high of $50.25. The stock has a 50-day moving average of $47.35 and a 200-day moving average of $46.34. The company’s market cap is $1.583 billion.

Integra LifeSciences Holdings Corp. (NASDAQ:IART) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.04. The company had revenue of $231.40 million for the quarter, compared to the consensus estimate of $229.32 million. During the same quarter in the previous year, the company posted $0.60 earnings per share. The company’s revenue for the quarter was up 12.6% on a year-over-year basis. Analysts expect that Integra LifeSciences Holdings Corp. will post $2.95 EPS for the current fiscal year.

Several other analysts have also recently commented on the stock. Analysts at Jefferies Group raised their price target on shares of Integra LifeSciences Holdings Corp. from $54.00 to $57.00 in a research note on Wednesday. Analysts at Zacks reiterated a “neutral” rating on shares of Integra LifeSciences Holdings Corp. in a research note on Thursday, July 3rd. They now have a $50.00 price target on the stock. Five equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $52.25.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is an integrated medical technology company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.